

RECEIVED
CENTRAL FAX CENTER

NOV 09 2006

CV01148KB

10/777,849

IN THE CLAIMS


Please amend the claims as follows:

1. (Cancelled)
2. (Previously presented) The compound according to claim 45, where, R^1 is an alkyl or aryl group, with or without the one or more substituents.
3. (Previously presented) The compound according to claim 2, where, R^1 is a methyl, ethyl or benzyl group, with or without the one or more substituents.
4. (Previously presented) The compound according to claim 45, where, R^2 is an alkyl group, with or without the one or more substituents.
5. (Previously presented) The compound according to claim 4, where, R^2 is a methyl, ethyl, iso-butyl or hydroxyethyl group, with or without the one or more substituents.
6. (Previously presented) The compound according to claim 45, where, R^3 is an aryl group, with or without the one or more substituents.
7. (Previously presented) The compound according to claim 6, where, R^3 is a hydroxyaryl, alkoxyaryl or aminosulfonylaryl group, with or without the one or more substituents.
8. (Previously amended) The compound according to claim 7, where, the hydroxyaryl, alkoxyaryl or aminosulfonylaryl group for R^3 is substituted with at least one halogen atom on the aryl ring.
9. (Previously presented) The compound according to claim 45, where, R^4 is a heterocycloalkyl group, with or without the one or more substituents.

CV01148KB

10/777,849


10. (Previously presented) The compound according to claim 9, where, R^4 is a tetrahydropyranyl group, with or without the one or more substituents.
11. (Previously presented) The compound according to claim 45, where, R^1 is a methyl or ethyl group, R^2 is a methyl, ethyl or hydroxyethyl group, R^3 is a 3-chloro-4-hydroxyphenyl, 3-bromo-4-hydroxyphenyl, 3-chloro-4-methoxyphenyl, 3-bromo-4-methoxyphenyl, or 4-aminosulfonylphenyl group and R^4 is a tetrahydropyranyl group.
12. (Previously presented) The compound according to claim 45, where, R^1 is an alkyl or aryl group, with or without the one or more substituents, R^2 is an alkyl group, with or without the one or more substituents, and R^3 is a 4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 3-bromo-4-hydroxyphenyl, 4-methoxyphenyl, 3-chloro-4-methoxyphenyl, 3-bromo-4-methoxyphenyl, 4-aminosulfonylphenyl, 3-chloro-4-aminosulfonylphenyl or 3-bromo-4-aminosulfonylphenyl group.
- 13-21. (Cancelled)
22. (Previously presented) The compound according to claim 45, which is:



CV01148KB

10/777,849

23. (Previously presented) The compound according to claim 45, which is:



24-33. (Cancelled)

34. (Previously presented) A method for elevating a cGMP level in a patient in need of the treatment, comprising administering to the patient an effective amount of the compound according to claim 45.

35. (Previously presented) A method for treating an erectile dysfunction in a patient in need of the treatment, comprising administering to the patient an effective amount of at least one of the compound according to claim 45.

36. (Cancelled)

37. (Cancelled)

38. (Cancelled)

39. (Previously presented) A method for treating an erectile dysfunction or another symptom, disease or disorder in a patient in need of the treatment, comprising administering to the patient a combination therapy, comprising a therapeutically effective amount of at least one compound according to claim 45 and at least one compound selected from the group consisting of: a prostanoid,

CV01148KB



10/777,849

α -adrenergic receptor, dopamine receptor agonist, melanocortin receptor agonist, endothelin receptor antagonist, endothelin converting enzyme inhibitor, angiotensin II receptor antagonist, angiotensin converting enzyme inhibitor, neutral metalloendopeptidase inhibitor, renin inhibitor, serotonin 5-HT_{2c} receptor agonist, nociceptin receptor agonist, rho kinase inhibitor, potassium channel modulator and multidrug resistance protein 5 inhibitor.

40. (Cancelled)

41. (Previously presented) A pharmaceutical composition comprising a compound, enantiomer, stereoisomer, rotomer or tautomer of claim 45 or pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

42. (Previously presented) The pharmaceutical composition according to claim 41, wherein the compound is:




43. (Cancelled)

44. (Cancelled)

10/777,849

CV01148KB

45. (Previously presented) A compound of Formula (I), an enantiomer, stereoisomer, rotomer, tautomer or a pharmaceutically acceptable salt thereof:




where,

- (a) R^1 and R^2 are, independently of one another, each a C_{1-15} alkyl group, branched or straight chain, unsubstituted or substituted with one or more substituents, a C_{2-15} alkenyl group, branched or straight chain, unsubstituted or substituted with one or more substituents, a C_{2-15} alkynyl group, branched or straight chain, unsubstituted or substituted with one or more substituents, a C_{3-15} cycloalkyl group, unsubstituted or substituted with one or more substituents, an arylalkyl group, unsubstituted or substituted with one or more substituents, an aryl group, unsubstituted or substituted with one or more substituents, a heteroaryl group, unsubstituted or substituted with one or more substituents, $-OR^5$, $-COOR^5$, $-C(O)R^5$ or $-C(O)N(R^5)_2$, where, R^5 is a hydrogen atom or a hydrocarbon radical, unsubstituted or substituted with one or

CV01148KB

10/777,849

more substituents, or one of R^1 and R^2 is a hydrogen atom and the other one of R^1 and R^2 is defined the same as above;



- (b) R^3 is an aryl group, unsubstituted or substituted with one or more substituents, a heteroaryl group, unsubstituted or substituted with one or more substituents, or a heterocyclic group having 1 to 3 heteroatoms fused to a 5- or 6-membered aryl ring, unsubstituted or substituted with one or more substituents, with the proviso that R^3 is not an aryl group substituted at its para position with a -Y-aryl group, where, Y is a carbon-carbon single bond, -C(O)-, -O-, -S-, -N(R^{21})-, -C(O)N(R^{22})-, -N(R^{22})C(O)-, -OCH₂-, -CH₂O-, -SCH₂-, -CH₂S-, -N(H)C(R^{23})(R^{24})-, -N(R^{23})S(O₂)-, -S(O₂)N(R^{23})-, -C(R^{23})(R^{24})N(H)-, -CH=CH-, -CF=CF-, -CH=CF-, -CF=CH-, -CH₂CH₂-, -CF₂CF₂-,

where,

R^{21} is a hydrogen atom or a -CO(C₁₋₄ alkyl), C₁₋₆ alkyl, allyl, C₃₋₆ cycloalkyl, phenyl or benzyl group;

R^{22} is a hydrogen atom or a C₁₋₆ alkyl group;

R^{23} is a hydrogen atom or a C₁₋₅ alkyl, aryl or -CH₂-aryl group;

10/777,849

CV01148KB


R^{24} is a hydrogen atom or a C_{1-4} alkyl group;

R^{25} is a hydrogen atom or a C_{1-8} alkyl, C_{1-8} perfluoroalkyl,

C_{3-8} cycloalkyl, phenyl or benzyl group;

R^{26} is a hydrogen atom or a C_{1-8} alkyl, C_{3-8} cycloalkyl, phenyl or benzyl group;

R^{27} is $-NR^{23}R^{24}$, $-OR^{24}$, $-NHCONH_2$, $-NHCSNH_2$,



and

R^{28} and R^{29} are, independently of one another, each a C_{1-4} alkyl group or, taken together with each other, a $-(CH_2)_q$ group, where q is 2 or 3; and

(c) R^4 is a heterocycloalkyl group of 3 to 15 members unsubstituted or substituted with one or more substituents;

wherein, the one or more substituents for all the groups are chemically-compatible and are, independently of one another, each an: alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, arylalkyl, alkylaryl, aryl, heteroaryl, heterocycloalkyl, hydroxyalkyl, arylalkyl, aminoalkyl, haloalkyl, alkylthioalkyl, carboxyalkyl, imidazolylalkyl, indolylalkyl, mono-, di- and trihaloalkyl, mono-, di- and trihaloalkoxy, amino, alkylamino, dialkylamino, alkoxy, hydroxy, halo, nitro, oximino, $-COOR^{50}$, $-COR^{50}$, $-SO_{0-2}R^{50}$, -

CV01148KB

10/777,849

$\text{SO}_2\text{NR}^{50}\text{R}^{51}$, $\text{NR}^{52}\text{SO}_2\text{R}^{50}$, $=\text{C}(\text{R}^{50}\text{R}^{51})$, $=\text{N}-\text{OR}^{50}$, $=\text{N}-\text{CN}$, $=\text{C}(\text{halo})_2$, $=\text{S}$,
 $=\text{O}$, $-\text{CON}(\text{R}^{50}\text{R}^{51})$, $-\text{OCOR}^{50}$, $-\text{OCON}(\text{R}^{50}\text{R}^{51})$, $-\text{N}(\text{R}^{52})\text{CO}(\text{R}^{50})$, $-\text{N}(\text{R}^{52})\text{COOR}^{50}$ or $-\text{N}(\text{R}^{52})\text{CON}(\text{R}^{50}\text{R}^{51})$ group, where:


R^{50} , R^{51} and R^{52} are, independently of one another, each a hydrogen atom or a branched or straight-chain, optionally substituted, C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{4-6} heterocycloalkyl, heteroaryl or aryl group, or R^{50} and R^{51} together with the atom to which they are attached together form a carbocyclic or heterocyclic ring system,

wherein the optional substituents are defined above for the one or more

substituents.

46. (Previously presented) A method for producing a compound having the formula (I), comprising:

- (i) reacting a compound having the formula (III) with L-halide in the presence of a base to form a compound having the formula (IV):



where,

- (a) R^1 is a hydrogen atom or a C_{1-15} alkyl group, branched or straight chain, unsubstituted or substituted with one or more substituents, a

CV01148KB


10/777,849

C₂₋₁₅ alkenyl group, branched or straight chain, unsubstituted or substituted with one or more substituents, a C₂₋₁₅ alkynyl group, branched or straight chain, unsubstituted or substituted with one or more substituents, a C₃₋₁₅ cycloalkyl group, unsubstituted or substituted with one or more substituents, an arylalkyl group, unsubstituted or substituted with one or more substituents, an aryl group, unsubstituted or substituted with one or more substituents, a heteroaryl group, unsubstituted or substituted with one or more substituents, -OR⁵, -COOR⁵, -C(O)R⁵ or -C(O)N(R⁵)₂, where R⁵ is a hydrogen atom or a hydrocarbon radical, branched or straight-chain, unsubstituted or substituted with one or more substituents;

(b) L is R² or a protected form of R²; and

(c) Ph is a phenyl group;

(ii) debenzylating and then reacting the compound having the formula (IV) with a halide having the formula XCH₂R³ to form the compound having the formula (V):




10/777,849

CV01148KB

where,

X is a halogen atom and

R³ is an aryl group, unsubstituted or substituted with one or more substituents, a heteroaryl group, unsubstituted or substituted with one or more substituents, or a heterocyclic group having 1 to 3 heteroatoms fused to a 5- or 6-membered aryl ring, unsubstituted or substituted with one or more substituents, with the proviso that R³ is not an aryl group substituted at its para position with a -Y-aryl group, where Y is a carbon-carbon single bond, -CO-, -O-, -S-, -N(R²¹)-, -CON(R²²)-, -N(R²²)CO-, -OCH₂-, -CH₂O-, -SCH₂-, -CH₂S-, -NHC(R²³)(R²⁴)-, -NR²³SO₂-, -SO₂NR²³-, -C(R²³)(R²⁴)NH-, -CH=CH-, -CF=CF-, -CH=CF-, -CF=CH-, -CH₂CH₂-, -CF₂CF₂-,



where,

R²¹ is a hydrogen atom or a -CO(C₁₋₄ alkyl), C₁₋₆ alkyl, allyl, C₃₋₆ cycloalkyl, phenyl or benzyl group;

R²² is a hydrogen atom or a C₁₋₆ alkyl group;

10/777,849

CV01148KB

R^{23} is a hydrogen atom or a C_{1-5} alkyl, aryl or $-CH_2$ -aryl group;


R^{24} is a hydrogen atom or a C_{1-4} alkyl group;

R^{25} is a hydrogen atom or a C_{1-8} alkyl, C_{1-8} perfluoroalkyl;

C_{3-6} cycloalkyl, phenyl or benzyl group;

R^{26} is a hydrogen atom or a C_{1-6} alkyl, C_{3-6} cycloalkyl, phenyl or benzyl group;

R^{27} is $-NR^{23}R^{24}$, $-OR^{24}$, $-NHCONH_2$, $-NHCSNH_2$.



and


R^{28} and R^{29} are, independently of one another, each a C_{1-4} alkyl group, or R^{28} and R^{29} , taken together with each other, are a $-(CH_2)_q$ group, where q is 2 or 3;

wherein, R^{21} through R^{29} are optionally substituted with one or more substituents; and

- (iii) deprotonating and then halogenating the compound having the formula (V) to form a compound having the formula (VI):

10/777,849


CV01148KB



where,

Hal is a halogen atom;

- (iv) reacting the compound having the formula (VI) with an amine having the formula R^4NH_2 to form a compound having the formula (VII):




where,

R^4 is a heterocycloalkyl group of 3 to 15 members, with or without unsubstituted or substituted with one or more substituents; and

- (v) removing the protecting portion of L, when L is the protected form of R^2 , on the compound having the formula (VII) to form the compound having the formula (I):

10/777,849

CV01148KB



where,

R^2 is defined the same as R^1 above, with the proviso that at least one of R^1 and R^2 is not a hydrogen atom;

wherein, the one or more substituents for all the groups are chemically-compatible and are, independently of one another, each an: alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, arylalkyl, alkylaryl, aryl, heteroaryl, heterocycloalkyl, hydroxyalkyl, arylalkyl, aminoalkyl, haloalkyl, alkylthioalkyl, carboxyalkyl, imidazolylalkyl, indolylalkyl, mono-, di- and trihaloalkyl, mono-, di- and trihaloalkoxy, amino, alkylamino, dialkylamino, alkoxy, hydroxy, halo, nitro, oximino, $-\text{COOR}^{50}$, $-\text{COR}^{50}$, $-\text{SO}_{0.2}\text{R}^{50}$, $-\text{SO}_2\text{NR}^{50}\text{R}^{51}$, $\text{NR}^{52}\text{SO}_2\text{R}^{50}$, $=\text{C}(\text{R}^{50}\text{R}^{51})$, $=\text{N}-\text{OR}^{50}$, $=\text{N}-\text{CN}$, $=\text{C}(\text{halo})_2$, $=\text{S}$, $=\text{O}$, $-\text{CON}(\text{R}^{50}\text{R}^{51})$, $-\text{OCOR}^{50}$, $-\text{OCON}(\text{R}^{50}\text{R}^{51})$, $-\text{N}(\text{R}^{52})\text{CO}(\text{R}^{50})$, $-\text{N}(\text{R}^{52})\text{COOR}^{50}$ or $-\text{N}(\text{R}^{52})\text{CON}(\text{R}^{50}\text{R}^{51})$ group, where:

R^{50} , R^{51} and R^{52} are, independently of one another, each a hydrogen atom or a C_{1-6} alkyl, C_{3-6} cycloalkyl, C_{4-6} heterocycloalkyl, heteroaryl and aryl group, or R^{50} and R^{51} together with the atom to which they are attached together form a carbocyclic or heterocyclic ring system,

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.